<DOC>
	<DOCNO>NCT01481493</DOCNO>
	<brief_summary>The study conduct order find repeated dos monoclonal ( artificially manufacture ) antibody BT061 help arthritis patient whose disease sufficiently respond treatment methotrexate ( MTX ) .</brief_summary>
	<brief_title>Dose-finding Multiple Dose BT061 Patients With Active Rheumatoid Arthritis Incompletely Controlled Stable Methotrexate ( MTX )</brief_title>
	<detailed_description>Patients show active rheumatoid arthritis accord ACR criterion despite least 6 month treatment methotrexate fulfil inclusion criterion include write informed consent none exclusion criterion ( see ) opportunity randomise either treatment BT061 placebo , give subcutaneously double-blind set-up .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients active Rheumatoid Arthritis ( RA ) accord 1987 revised ACR criterion functional class IIIII Disease activity screen baseline ( 6 swell joint count ; 6 tender joint count ; elevat . CRP ESR ) Duration RA 12 month History least one diseasemodifying antirheumatic drug ( DMARD ) inadequate response despite 3 month treatment MTX treatment least 6 month stable dose least 15mg MTX Patients could continue daily 7,5mg prednisone equivalent stable dose least 6 week prior baseline Written Informed Consent Treatment traditional DMARDs apart MTX 12 week prior baseline DMARD leflunomide 24 week Treatment biologics TNFα inhibitor ( e.g . abatacept , rituximab , tocilizumab , anakinra ) treatment TNFα inhibitor within 5 elimination halflives prior baseline study Clinical nonresponse one TNFα inhibitor exceed adequate treatment duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
</DOC>